姓名 | 職稱 | 持有股份 | 代表法人 |
---|---|---|---|
Yang,Chao-Tang | Chairman | 8.31% | Veritas Biomedical Co. Ltd. |
Lin,Liang-Guang | Director | 8.31% | Veritas Biomedical Co. Ltd. |
Chen,Ji-Guang | Director | 5.77% | BECQUEREL & SIEVERT CO., LTD. |
Jiang,Zheng-Qi | Director | 5.32% | GIDDI PHARMA CO., LTD. |
Cai,Shi-Chen | Independent Director | 0.00% | |
Huang,Shi-Ying | Independent Director | 0.00% | |
Qian,Ying-Long | Independent Director | 0.00% |
項目 | 2024 | 2023 |
---|---|---|
Operating income | 55,936 | 117,866 |
Operating cost | 26,704 | 53,274 |
Profit (loss) of initial recognition of biological asset and agricultural products | - | - |
Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - |
Operating gross profit (loss) | 29,232 | 64,592 |
Unrealized profit (loss) on sales of goods | - | - |
Realized profit (loss) on sales of goods | - | - |
Operating gross profit (loss), net | 29,232 | 64,592 |
Operating expenses | 27,768 | 57,005 |
Other gain (loss), net | - | - |
Operating profit (loss) | 1,464 | 7,587 |
Non-operating income and expenses | 1,901 | 1,562 |
Net profit (loss) before tax | 3,365 | 9,149 |
Income tax expense (benefits) | 0 | 0 |
Net profit (loss) of ongoing business for the current period | 3,365 | 9,149 |
Profit (loss) of closed units | - | - |
Profit (loss) of non-jointly controlled equity before merger | - | - |
Net profit (loss) for the current period | 3,365 | 9,149 |
Other comprehensive profit (loss), net | - | 0 |
Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - |
Total comprehensive profit and loss for the current period | 3,365 | 9,149 |
Net profit (loss) attributable to owners of parent company | - | - |
Net profit (loss) form equity attributable to former owner of business combination under common control | - | - |
Net profit (loss) attributable to non-controlling interests | - | - |
Comprehensive profit (loss) attributable to owners of parent company | - | - |
Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - |
Comprehensive profit (loss) attributable to non-controlling interests | - | - |
Basic earnings per share (yuan) | 0 | 0 |
項目 | 2024 | 2023 |
---|---|---|
Net cash inflow (outflow) from operating activities | - | - |
Net cash inflows (outflows) from investing activities | - | - |
Net cash inflow (outflow) from financing activities | - | - |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - |
Increase (decrease) in cash and cash equivalents in the current period | - | - |
Beginning balance of cash and cash equivalents | - | - |
Ending balance of cash and cash equivalents | - | - |
項目 | 2024 | 2023 |
---|---|---|
Current asset | 363,298 | 354,404 |
Non-current asset | 298,922 | 133,173 |
Total asset | 662,220 | 487,577 |
Current liability | 135,488 | 32,309 |
Non-current liability | 39,371 | 41,630 |
Total liability | 174,859 | 73,939 |
share capital | 405,294 | 371,899 |
Equity - secruity token | - | - |
capital reserve | 78,702 | 150,005 |
retained earning | 3,365 | -108,266 |
Other equity | 0 | 0 |
Treasury stock | - | - |
Total equity attributable to owners of parent company | - | - |
Equity attributable to former owner of business combination under common control | - | - |
Equity attributable to non-controlling interest before business merger under common control | - | - |
Non-controlling interests | - | - |
Total Equity | 487,361 | 413,638 |
Share capital awaiting retirement (unit: share) | 0 | 0 |
Issued shares of advance equity (unit: shares) | 0 | 0 |
Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 |
Net asset value per share | 12 | 11 |